본문 바로가기
KERD
논문KCI 등재

The Role of Monoclonal Antibody in Combination with First-Line Chemotherapy in Asian Patients with Advanced Non-Small Cell Lung Cancer

김주항|조병철|Ross A Soo|Chih-Hsin Yang
연세대학교의과대학 (Yonsei University College of Medicine)|2010.01|Yonsei Medical Journal|제51권 제1호|pp. 1-8

2

조회

0

다운로드

1

인용

0

참고문헌

키워드

chemotherapymonoclonal antibodyNon-small cell lung cancercetuximabbevacizumab
주제분류의학일반

초록

The strategies of incorporating monoclonal antibodies (MoABs) have now proved efficacy in the first-line treatment of advanced non-small cell lung cancer (NSCLC). These include targeting the vascular endothelial growth factor (VEGF) or epidermal growth factor receptor (EGFR). Bevacizumab is a MoAB targeting the vascular endothelial growth factor (VEGF), an important mediator of new blood vessel formation. Cetuximab is a MoAB directed at EGFR. Binding cetuximab to EGFR blocks signal transduction and promotes receptor internalization and degradation. In this review, we present current data of bevacizumab and cetuximab for the first line treatment of advanced NSCLC. We also refer to their potential for Asian patients with advanced NSCLC in the first-line setting.

Abstract

The strategies of incorporating monoclonal antibodies (MoABs) have now proved efficacy in the first-line treatment of advanced non-small cell lung cancer (NSCLC). These include targeting the vascular endothelial growth factor (VEGF) or epidermal growth factor receptor (EGFR). Bevacizumab is a MoAB targeting the vascular endothelial growth factor (VEGF), an important mediator of new blood vessel formation. Cetuximab is a MoAB directed at EGFR. Binding cetuximab to EGFR blocks signal transduction and promotes receptor internalization and degradation. In this review, we present current data of bevacizumab and cetuximab for the first line treatment of advanced NSCLC. We also refer to their potential for Asian patients with advanced NSCLC in the first-line setting.

참고문헌 (32)

  1. Johnson DH, "Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer", J Clin Oncol, 22, pp.2184~2191 (2004)
  2. Sandler A, "Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer", N Engl J Med, 355, pp.2542~2550 (2006)
  3. Reck M, "Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer", AVAil. J Clin Oncol, 27, pp.1227~1234 (2009)
  4. Jänne PA, "Epidermal growth factor receptor mutations in non-small cell lung cancer: implications for treatment and tumor biology", J Clin Oncol, 23, pp.3227~3234 (2005)
  5. Dowlati A, "Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab--an Eastern Cooperative Oncology Group Study", Clin Cancer Res, 14, pp.1407~1412 (2008)
  6. Manegold C, "BO17704 (AVAiL): a phase III randomised study of first-line bevacizumab combined with cisplatin", gemcitabine in patients with advanced or recurrent non-squamous, non-small cell lung cancer (NSCLC), 2008, pp.19, ~
  7. Pirker R, "FLEX: a randomized, multicenter, phase III study of cetuximab in combination with cisplatin", vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC), 2008, pp.26, ~
  8. Sandler AB, "Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with carboplatin and paclitaxel plus bevacizumab", J Clin Oncol, 27, pp.1405~1412 (2009)
  9. Gordon MS, "Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer", J Clin Oncol, 19, pp.843~850 (2001)
  10. Akerley WL, "Acceptable safety of bevacizumab therapy in patients with brain metastases due to non-small cell lung cancer", J Clin Oncol, 26 (2008)
  11. Archer V, "Risk of symptomatic central nervous system (CNS) progression and secondary hemorrhage in patients with nonsquamous non-small cell lung cancer (NSCLC) receiving bevacizumab(BV)-based first-line therapy", J Clin Oncol, 26 (2008)
  12. Dansin E, "Safety of bevacizumab-based therapy as first-line treatment of patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): MO19390 (SAiL)", J Clin Oncol, 26 (2008)
  13. Griesinger F, "on behalf of the MO19390(SAiL) study group. Safety of first-line bevacizumab-based therapy with concomitant cardiovascular or anticoagulation medication in advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) in MO19390 (SAiL)", J Clin Oncol, 26 (2008)
  14. Vosseler S, "Angiogenesis inhibition by vascular endothelial growth factor receptor-2 blockade reduces stromal matrix metalloproteinase expression, normalizes stromal tissue, and reverts epithelial tumor phenotype in surface heterotransplants", Cancer Res, 65, pp.1294~1305 (2005)
  15. Hurwitz H, "Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer", N Engl J Med, 350, pp.2335~2342 (2004)
  16. Ramalingam SS, "Outcomes for elderly, advanced-stage nonsmall-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599", J Clin Oncol, 26, pp.60~65 (2008)
  17. Nishio M, "Randomized, open-label, multicenter phase II sutdy of bevacizumab in combination with carboplatin and paclitaxel in chemotherapy-naive Japanese patients with advanced or recurrent nonsquamous non-small cell lung cancer (NSCLC): JO19907", J Clin Oncol, 27 (2009)
  18. Dowlati A, "Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab--an Eastern Cooperative Oncology Group Study", Clin Cancer Res, 14, pp.1407~1412 (2008)
  19. Leighl N, "Analysis of biomarkers in the AVAiL phase III randomised study of first-line bevacizumab with cisplatin-gemcitabine in patients with non-small cell lung cancer", Eur J Cancer, 7 (2009)
  20. Rosell R, "Randomized phase II study of cetuximab plus cisplatin", vinorelbine compared with cisplatin, Ann Oncol, pp.2008, 19[DOI]
  21. , with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer, "J Clin Oncol", 2007, 5777~5784
  22. Lynch TJ, "Overall survival results from the phase III trial BMS 099: Cetuximab + taxane", carboplatin as 1st-line treatment for advanced NSCLC, 2008, pp.3, S305~
  23. Pirker R, "Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer(FLEX): an open-label randomised phase III trial", Lancet, 373, pp.1525~1531 (2009)
  24. Nick T, "Cetuximab plus platinum-based chemotherapy as 1st-line treatment in patients with non-small cell lung cancer (NSCLC): a meta-analysis of randomized phase II", III trials, 2009, pp.4, S297~
  25. Pirker R, "FLEX: a randomized, multicenter, phase III study of cetuximab in combination with cisplatin", vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC), 2008, pp.26, ~
  26. Chung KY, "Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry", J Clin Oncol, 23, pp.1803~1810 (2005)
  27. Cappuzzo F, "EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients", Ann Oncol, 19, pp.717~723 (2008)
  28. Hirsch FR, "Increased EGFR gene copy number detected by fluorescent In situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy", J Clin Oncol, 26, pp.3351~3357 (2008)
  29. Khambata-Ford S, "Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab", J Clin Oncol, 25, pp.3230~3237 (2007)
  30. Frattini M, "PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients", Br J Cancer, 97, pp.1139~1145 (2007)
  31. Peréz-Soler R, "Cutaneous adverse effects with HER1", EGFR-targeted agents: is there a silver lining?, 2005, pp.23, 5235~5246
  32. Gatzemeier U, "Molecular and clinical biomarkers of cetuximab efficacy: data from the phase III FLEX study in nonsmall cell lung cancer (NSCLC)", J Thorac Oncol, 4, pp.S324~ (2009)

관련 논문AI추천

진행성 비소세포폐암의 표적치료 및 맞춤항암치료윤탁대한내과학회 · 대한내과학회지2009 · 제77권 제1호Epidermal Growth Factor Receptor Mutation Status in the Treatment of Non-small Cell Lung Cancer: Lessons Learned이대호, Mauro Orlando, Rebecca Cheng, Vichien Srimuninnimit, Xin Wang대한암학회 · Cancer Research and Treatment2015 · 제47권 제4호The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung AdenocarcinomaChun-Shih Chin, Gee-Chen Chang, Jeng-Sen Tseng, Jeremy J.W. Chen, Kang-Yi Su, Kun-Chieh Chen, Kuo-Hsuan Hsu, Sung-Liang Yu, Tsung-Ying Yang, Yen-Hsiang Huang대한암학회 · Cancer Research and Treatment2022 · 제54권 제2호Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations김기환, 김동완, 김범석, 김세현, 김유정, 김진수, 김태민, 박세훈, 이세훈, 이종석, 허대석대한암학회 · Cancer Research and Treatment2015 · 제47권 제4호Treatment of Non-small Cell Lung Carcinoma after Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor김영철, 이계영, 이재철, 장승훈대한암학회 · Cancer Research and Treatment2013 · 제45권 제2호Early or Late Gefitinib, Which is Better for Survival? - Retrospective Analysis of 228 Korean Patients with Advanced or Metastatic NSCLC고성애, 김동근, 김명진, 김민경, 김현제, 박성우, 배성화, 신경철, 이경희, 이관호, 장효진, 정진홍, 현명수영남대학교 의과대학 · Journal of Yeungnam Medical Science2011 · 제28권 제1호

이 간행물의 다른 논문 (14건)

Early Initiation of Alcohol Drinking, Cigarette Smoking, and Sexual Intercourse Linked to Suicidal Ideation and Attempts: Findings from the 2006 Korean Youth Risk Behavior Survey김현선, 김동식pp. 18-26No Evidence of an Association between A218C Polymorphism of the Tryptophan Hydroxylase 1 Gene and Aggression in Schizophrenia in a Korean Population민성길, 이주영, 김율리pp. 27-32Endoscopic Evaluation of Gastric Emptying and Effect of Mosapride Citrate on Gastric Emptying정인수, 김지현, 이상인, 박효진, 이활윤pp. 33-38Delivery of Factor VIII Gene into Skeletal Muscle Cells Using Lentiviral Vector오태근, 김옥희, 김승택, 전현정pp. 52-57Long-Term Clinical Outcomes according to Initial Management and Thrombolysis In Myocardial Infarction Risk Score in Patients with Acute Non-ST-Segment Elevation Myocardial Infarction나승운, 김종진, 최동훈, 정해창, 홍택종, Other Korea Acute Myocardial Infarction Registry Investigators, 정욱성, 안영근, 정명호, 조정관, 채성철, 장양수, 윤정한, 허승호, 김영조, 배장호, 성인환, 채제건, 조명찬, 류재영, 승기배, 채인호pp. 58-68
원문 보기